9
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Platforms and Artificial Intelligence in Dementia

      Submit here by August 31, 2025

      About Dementia and Geriatric Cognitive Disorders: 2.2 Impact Factor I 4.7 CiteScore I 0.809 Scimago Journal & Country Rank (SJR)

      Call for Papers: Skin Health in Aging Populations

      Submit here by August 31, 2025

      About Skin Pharmacology and Physiology: 2.8 Impact Factor I 5.2 CiteScore I 0.623 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Mortality and Autopsy Findings in Patients with Pyoderma Gangrenosum: A Multi-Institutional Series

      brief-report

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Pyoderma gangrenosum (PG) is a rare ulcerative skin condition with an increased risk of mortality compared to the general population. The causes of this increased risk are not well understood. Misdiagnosis is common in PG, and many studies are limited by the inclusion of misdiagnosed cases. The goal of this study was to review autopsy findings, identify causes of death, and identify factors that may worsen outcomes among deceased patients confirmed to have PG. Methods: Data was retrospectively reviewed from the electronic medical records at five academic hospitals. A search was conducted for deceased patients with a diagnosis of PG who had an autopsy performed between 2010 and 2020. We report a descriptive analysis of 11 patients and their clinical characteristics, causes of death, and autopsy findings. Results: The average age of death was 62.9 years. Seven patients had at least one underlying condition known to be associated with PG including inflammatory bowel disease, inflammatory arthritis, or a hematologic disorder. The most common cause of death was infection ( n = 6, 54.5%), followed by pulmonary embolism ( n = 3, 27.3%), and myelodysplastic syndrome ( n = 2, 18.2%). Six patients (54.5%) were taking systemic steroids at the time of death. Conclusion: The development of PG may shorten life expectancy among those with underlying conditions associated with PG, and common treatments for PG may contribute to the risk of fatal complications. Awareness of the risk of infection, thrombosis, and malignancy among those with PG is necessary for proper management. Further research is needed to explore the relationship between PG and thromboembolism.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Interplay between inflammation and thrombosis in cardiovascular pathology

          Thrombosis is the most feared complication of cardiovascular diseases and a main cause of death worldwide, making it a major health-care challenge. Platelets and the coagulation cascade are effectively targeted by antithrombotic approaches, which carry an inherent risk of bleeding. Moreover, antithrombotics cannot completely prevent thrombotic events, implicating a therapeutic gap due to a third, not yet adequately addressed mechanism, namely inflammation. In this Review, we discuss how the synergy between inflammation and thrombosis drives thrombotic diseases. We focus on the huge potential of anti-inflammatory strategies to target cardiovascular pathologies. Findings in the past decade have uncovered a sophisticated connection between innate immunity, platelet activation and coagulation, termed immunothrombosis. Immunothrombosis is an important host defence mechanism to limit systemic spreading of pathogens through the bloodstream. However, the aberrant activation of immunothrombosis in cardiovascular diseases causes myocardial infarction, stroke and venous thromboembolism. The clinical relevance of aberrant immunothrombosis, referred to as thromboinflammation, is supported by the increased risk of cardiovascular events in patients with inflammatory diseases but also during infections, including in COVID-19. Clinical trials in the past 4 years have confirmed the anti-ischaemic effects of anti-inflammatory strategies, backing the concept of a prothrombotic function of inflammation. Targeting inflammation to prevent thrombosis leaves haemostasis mainly unaffected, circumventing the risk of bleeding associated with current approaches. Considering the growing number of anti-inflammatory therapies, it is crucial to appreciate their potential in covering therapeutic gaps in cardiovascular diseases. In this Review, Stark and Massberg discuss how the interplay between innate immunity, platelet activation and coagulation, known as immunothrombosis, functions as a host defence mechanism to limit pathogen spreading, yet its aberrant activation, termed thromboinflammation, results in thrombotic complications, highlighting the therapeutic potential of anti-inflammatory strategies in cardiovascular pathologies. Inflammation and thrombosis are tightly connected processes that contribute to the containment of pathogen spreading in a host defence effector mechanism termed immunothrombosis. The dysregulated and excessive activation of immunothrombosis results in thromboinflammation, causing tissue ischaemia by microvascular and macrovascular thrombosis. The main factor in immunothrombosis and thromboinflammation is a vicious circle of platelet and innate immune cell activation, unleashing the complement system and coagulation cascade. Inflammatory conditions such as infection, chronic autoimmune diseases and clonal haematopoiesis of indeterminate potential are associated with an increased risk of thrombotic events, providing clinical evidence for the partnership between inflammation and thrombosis. Pulmonary immunothrombosis is a prominent feature of severe COVID-19, aggravating respiratory failure and correlating with a systemic prothrombotic phenotype. The inflammatory component of thrombosis is a therapeutic gap and a promising target for the prevention and treatment of cardiovascular diseases such as myocardial infarction, stroke and venous thromboembolism.
            • Record: found
            • Abstract: found
            • Article: not found

            The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.

            There is an impression mostly from specialty clinics that patients with inflammatory bowel disease (IBD) have an increased risk of venous thromboembolic disorders. Our aim was to determine the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE) from a population-based database of IBD patients and, to compare the incidence rates to that of an age, gender and geographically matched population control group. IBD patients identified from the administrative claims data of the universal provincial insurance plan of Manitoba were matched 1:10 to randomly selected members of the general population without IBD by year, age, gender, and postal area of residence using Manitoba Health's population registry. The incidence of hospitalization for DVT and PE was calculated from hospital discharge abstracts using ICD-9-CM codes 451.1, 453.x for DVT and 415.1x for PE. Rates were calculated based on person-years of follow-up for 1984-1997. Comparisons to the population cohort yielded age-adjusted incidence rate ratios (IRR). Rates were calculated based on person-years of follow-up (Crohn's disease = 21,340, ulcerative colitis = 19,665) for 1984-1997. In Crohn's disease the incidence rate of DVT was 31.4/10,000 person-years and of PE was 10.3/10,000 person-years. In ulcerative colitis the incidence rates were 30.0/10,000 person-years for DVT and 19.8/10,000 person-years for PE. The IRR was 4.7 (95% CI, 3.5-6.3) for DVT and 2.9 (1.8-4.7) for PE in Crohn's disease and 2.8 (2.1-3.7) for DVT and 3.6 (2.5-5.2) for PE, in ulcerative colitis. There were no gender differences for IRR. The highest rates of DVT and PE were seen among patients over 60 years old; however the highest IRR for these events were among patients less than 40 years. IBD patients have a threefold increased risk of developing DVT or PE.
              • Record: found
              • Abstract: found
              • Article: not found

              Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study.

              Pyoderma gangrenosum (PG) is an important disease with significant complications. The objectives of this study were to determine incidence and mortality of PG and strength of reported associations. A retrospective cohort study was completed using computerized medical records from the General Practice Research Database, a large representative UK database. Patients with PG and three groups of age-, sex-, and practice-matched controls--general population, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) controls--were included in the study. Incidence and mortality were determined and validation undertaken to inform diagnostic accuracy. In all there were 313 people with the median age of 59 (interquartile range 41-72) years, and of them 185 (59%) were female. The adjusted incidence rate standardized to European standard population was 0.63 (95% confidence interval (CI) 0.57-0.71) per 100,000 person-years. The risk of death was three times higher than that for general controls (adjusted hazard ratio=3.03, 95% CI 1.84-4.73, P<0.001), 72% higher than that for IBD controls (adjusted hazard ratio=1.72, 95% CI 1.17-2.59, P=0.013), with a borderline increase compared with RA controls (adjusted hazard ratio=1.55, 95% CI 1.01-2.37, P=0.045). Disease associations were present in 110 (33%) participants: IBD, n=67 (20.2%); RA, n=39 (11.8%); and hematological disorders, n=13 (3.9%). To our knowledge, there are no previous population-based studies of the epidemiology of PG, an important disease with significantly increased mortality.

                Author and article information

                Journal
                DRM
                Dermatology
                10.1159/issn.1018-8665
                Dermatology
                Dermatology
                S. Karger AG
                1018-8665
                1421-9832
                2024
                April 2024
                06 January 2024
                : 240
                : 2
                : 352-356
                Affiliations
                [a ]Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA
                [b ]Oregon Health and Science University School of Medicine, Portland, Oregon, USA
                [c ]Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA
                [d ]Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts, USA
                [e ]Boston University School of Medicine, Boston, Massachusetts, USA
                [f ]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
                [g ]Division of Dermatology, University of Washington, Seattle, Washington, USA
                [h ]Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
                [i ]Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy
                [j ]Departments of Dermatology and Pathology, Cleveland Clinic, Cleveland, Ohio, USA
                Author notes
                *Alex G. Ortega-Loayza, ortegalo@ohsu.edu
                Article
                536145 Dermatology 2024;240:352–356
                10.1159/000536145
                38185115
                ae8f8b84-03a9-4aa3-b4f2-81d56b797349
                © 2024 S. Karger AG, Basel
                History
                : 30 June 2023
                : 03 January 2024
                Page count
                Tables: 1, Pages: 5
                Funding
                This study was not supported by any sponsor or funder.
                Categories
                Brief Report

                Medicine
                Mortality,Infection,Pyoderma gangrenosum,Autopsy
                Medicine
                Mortality, Infection, Pyoderma gangrenosum, Autopsy

                Comments

                Comment on this article

                Related Documents Log